A Phase II Trial of Docetaxel and Ifosfamide for Patients with Platinum-Resistant or Refractory Non-Small Cell Lung Cancer in a Salvage Setting.
- Author:
Gyeong Won LEE
1
;
Jung Hun KANG
;
Seok Hyun KIM
;
Hea Yong LEE
;
Ho Cheol KIM
;
Won Sup LEE
;
Jong Duk LEE
;
Young Sil HWANG
;
Joung Soon JANG
;
Jong Seok LEE
Author Information
1. Division of Hematology-Oncology, Departments of Internal Medicine, College of Medicine, Gyeong-Sang National University, Jinju, Korea.
- Publication Type:Original Article
- Keywords:
Non-small cell lung cancer;
Chemotherapy;
Docetaxel;
Ifosfamide;
Salvage therapy
- MeSH:
Carcinoma, Non-Small-Cell Lung*;
Disease Progression;
Drug Therapy;
Febrile Neutropenia;
Humans;
Ifosfamide*;
Infusions, Intravenous;
Lung Neoplasms;
Neutropenia;
Salvage Therapy
- From:Cancer Research and Treatment
2004;36(5):287-292
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We conducted a phase II study of docetaxel and ifosfamide chemotherapy for patients with platinum- resistant or refractory non-small-cell lung cancer (NSCLC) to evaluate the response and toxicity profiles as a salvage treatment. MATERIALS AND METHODS: Between July 2000 and July 2004, 40 patients who had previously received platinum- based regimen as the first-line or second-line therapy were enrolled in this study. The treatment consisted of a docetaxel 75 mg/m2 intravenous infusion on day 1 and intravenous ifosfamide 3 g/m2 with Mesna(R) uroprotectione on day 1 through 3. This regimen was repeated every 3 weeks. RESULTS: One hundred thirty cycles of treatment were given, with a median of 3 cycles (range: 2~6 cycles). All the patients were evaluable for the response rate and toxicity profile. The major toxicity was myelosuppression. Grade 3~4 neutropenia occurred in 30 patients (75%) during treatment. Febrile neutropenia occurred in 16 patients (40%). Five of 40 patients (12.5%) had a partial response (95% confidence interval, 3.3~21.7%). The median time to disease progression was 2.65 months (range: 2.02~3.20 months), and the median survival was 5.24 months (range: 2.99~7.49 months). CONCLUSION: Salvage chemotherapy with docetaxel and ifosfamide showed a low efficacy and a high proportion of severe neutropenia in patients with platinum-resistant or refractory advanced NSCLC.
